Jordi Rodon

Summary

Publications

  1. doi request reprint Molecular prescreening to select patient population in early clinical trials
    Jordi Rodon
    Medical Oncology Department, Vall d Hebron University Hospital, Spain
    Nat Rev Clin Oncol 9:359-66. 2012
  2. doi request reprint Development of PI3K inhibitors: lessons learned from early clinical trials
    Jordi Rodon
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Passeig Vall d Hebron 119, Edifici Maternoinfantil Planta 14, 08035 Barcelona, Spain
    Nat Rev Clin Oncol 10:143-53. 2013
  3. pmc Combining targeted therapies: practical issues to consider at the bench and bedside
    Jordi Rodon
    Servei d Oncologia Medica, Hospital Universitari Vall d Hebron, Vall d Hebron Institute of Oncology V H I O, Passatge Vall d Hebron 119, 08035 Barcelona, Spain
    Oncologist 15:37-50. 2010
  4. doi request reprint Biomarker-driven patient selection for early clinical trials
    Rodrigo Dienstmann
    Molecular Therapeutics Research Unit, Medical Oncology Department, Universitat Autonoma de Barcelona, Vall d Hebron University Hospital, Barcelona, Spain
    Curr Opin Oncol 25:305-12. 2013
  5. pmc Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Oncologist 16:1729-40. 2011
  6. doi request reprint A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
    Francesco Atzori
    Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 17:6304-12. 2011
  7. ncbi request reprint Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2
    Rodrigo Dienstmann
    Medical Oncology Service, Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, 08035, Spain
    Recent Pat Anticancer Drug Discov 6:210-36. 2011
  8. doi request reprint Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials
    Rodrigo Dienstmann
    Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mol Cancer Ther 11:2062-71. 2012
  9. doi request reprint Genomic medicine frontier in human solid tumors: prospects and challenges
    Rodrigo Dienstmann
    Vall d Hebron University Hospital, P Vall d Hebron 119 122, Barcelona, Spain 08035
    J Clin Oncol 31:1874-84. 2013

Detail Information

Publications9

  1. doi request reprint Molecular prescreening to select patient population in early clinical trials
    Jordi Rodon
    Medical Oncology Department, Vall d Hebron University Hospital, Spain
    Nat Rev Clin Oncol 9:359-66. 2012
    ....
  2. doi request reprint Development of PI3K inhibitors: lessons learned from early clinical trials
    Jordi Rodon
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Passeig Vall d Hebron 119, Edifici Maternoinfantil Planta 14, 08035 Barcelona, Spain
    Nat Rev Clin Oncol 10:143-53. 2013
    ..We also discuss key unresolved translational questions related to the clinical development of inhibitors of the PI3K/AKT/mTOR pathway and propose designs for biomarker-driven trials to address those issues...
  3. pmc Combining targeted therapies: practical issues to consider at the bench and bedside
    Jordi Rodon
    Servei d Oncologia Medica, Hospital Universitari Vall d Hebron, Vall d Hebron Institute of Oncology V H I O, Passatge Vall d Hebron 119, 08035 Barcelona, Spain
    Oncologist 15:37-50. 2010
    ..Recent technologies, such as multiplexed assay platforms and bioinformatics, will shape the future of clinical trials and help answer these questions surrounding combinatorial treatment...
  4. doi request reprint Biomarker-driven patient selection for early clinical trials
    Rodrigo Dienstmann
    Molecular Therapeutics Research Unit, Medical Oncology Department, Universitat Autonoma de Barcelona, Vall d Hebron University Hospital, Barcelona, Spain
    Curr Opin Oncol 25:305-12. 2013
    ..Technical and logistical obstacles that may hinder progress of this approach will be discussed, along with the ethical and financial concerns...
  5. pmc Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs
    Rodrigo Dienstmann
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Oncologist 16:1729-40. 2011
    ..Ultimately, the predictive value of a side effect of molecular targeted therapies requires validation in prospective trials...
  6. doi request reprint A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors
    Francesco Atzori
    Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Cancer Res 17:6304-12. 2011
    ..This study was designed to evaluate the safety and tolerability of dalotuzumab, determine the pharmacokinetic (PK) and pharmacodynamic (PD) profiles, and identify a recommended phase II dose...
  7. ncbi request reprint Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2
    Rodrigo Dienstmann
    Medical Oncology Service, Vall d Hebron University Hospital and Vall d Hebron Institute of Oncology, Universitat Autonoma de Barcelona, Barcelona, 08035, Spain
    Recent Pat Anticancer Drug Discov 6:210-36. 2011
    ..This review will focus primarily on an analysis of newly developed inhibitors of this pathway that have entered clinical trials, and recently registered patents in this field...
  8. doi request reprint Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials
    Rodrigo Dienstmann
    Molecular Therapeutics Research Unit, Medical Oncology Department, Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mol Cancer Ther 11:2062-71. 2012
    ..2%). These results suggest that matching chemorefractory patients with colorectal cancer with targeted agents in phase I trials based on the current molecular profile does not confer a significant clinical benefit...
  9. doi request reprint Genomic medicine frontier in human solid tumors: prospects and challenges
    Rodrigo Dienstmann
    Vall d Hebron University Hospital, P Vall d Hebron 119 122, Barcelona, Spain 08035
    J Clin Oncol 31:1874-84. 2013
    ....